Sign In
Buy MRTX
$58.70
+0 (+0%)
At Close: Apr 19, 2024
SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a post hoc exploratory analysis of the Pha
Mirati Therapeutics Appoints David Meek as Chief Executive Officer
07:55am, Monday, 20'th Sep 2021
SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of David Meek as Chief Executive Offic
SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive topline results from the potentially registrat
SAN DIEGO, Sept. 19, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a cohort of the Phase 1/2 KRYSTAL–1 stud
Mirati Therapeutics to Host Virtual Investor Event on Monday, September 20, 2021
04:15pm, Wednesday, 15'th Sep 2021
SAN DIEGO, Sept. 15, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the Company will host a virtual Investor Event on
SAN DIEGO, Aug. 25, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced two oral presentations of clinical data will be presente
3 Best Biotech Stocks To Buy for Upcoming Catalysts
06:00am, Thursday, 12'th Aug 2021
The next few months are critical for these biotech stocks which could witness a massive increase in their stock prices this year The post 3 Best Biotech Stocks To Buy for Upcoming Catalysts appeared f
Mirati Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Updates
04:15pm, Thursday, 05'th Aug 2021
SAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter of 2021 and recen
Mirati's (MRTX) Adagrasib Gets Breakthrough Therapy Status
02:17pm, Monday, 28'th Jun 2021
Mirati (MRTX) is developing adagrasib as a potential treatment for patients suffering from non-small cell lung cancer with KRAS mutation. An NDA is expected to be filed in the second half of 2021.
Mirati's KRAS Inhibitor Receives FDA Breakthrough Tag For Lung Cancer Harboring KRAS Mutation
09:27am, Friday, 25'th Jun 2021
The FDA has granted Breakthrough Therapy designation to Mirati Therapeutics Inc's (NASDAQ: MRTX) adagrasib in non-small cell lung cancer (NSCLC) patients with the KRAS-G12C mutation. The decision
SAN DIEGO, June 24, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced today that the U.S. Food and Drug Administration (FDA) has gra
Mirati Therapeutics to Take Part in the 42nd Annual Goldman Sachs Global Healthcare Conference
04:15pm, Wednesday, 02'nd Jun 2021
SAN DIEGO, June 2, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the 42nd Annual Goldman Sachs Globa
QIAGEN (QGEN)-Mirati Deal to Boost Companion Diagnostic Arm
06:46am, Thursday, 27'th May 2021
QIAGEN's (QGEN) alliance will facilitate co-development of KRAS companion diagnostic with Mirati's, adagrasib, a selective and potent oral inhibitor of KRAS G12C.
Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates
04:15pm, Thursday, 06'th May 2021
SAN DIEGO, May 6, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the first quarter of 2021 and recent c
Moving Average Crossover Alert: Mirati Therapeutics (MRTX)
07:31am, Monday, 03'rd May 2021
Mirati Therapeutics (MRTX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
